Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0000899243-17-021281

Chief Executive Officer sold 75,795 shares at an average $20.25 ($1,534,869)

  • Chief Executive Officer acquired 23,414 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Novak Rodger · Chief Executive Officer

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2017-08-28 Exercise or conversion : show line 1 in the form +17,692 $1.81 $32,023 1,232,697 D
2017-08-28 Sale : show line 2 in the form −17,692 $20.06 $354,919 1,215,005 D
2017-08-30 Exercise or conversion : show line 3 in the form +5,722 $1.81 $10,357 1,220,727 D
2017-08-30 Sale : show line 4 in the form −58,103 $20.31 $1,179,950 1,162,624 D
Open-market sales · 75,795 sh · avg $20.25 · $1,534,869

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2017-08-28 Exercise or conversion : show line 5 in the form Stock Options (Right to Buy) −17,692 50,401 D
2017-08-30 Exercise or conversion : show line 6 in the form Stock Options (Right to Buy) −5,722 44,679 D
Loading xslF345X03/doc4.xml…